Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 29, 2020 08:00 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Therapeutics Receives Positive EU CHMP Opinion for XENLETA™ (lefamulin) for the Treatment of Community-Acquired Pneumonia (CAP)

If approved, XENLETA has the potential to be a first-in-class pleuromutilin antibiotic for the intravenous (IV) and oral treatment of adult patients with CAP in Europe CHMP opinion supported by robust...
May 27, 2020 16:01 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Therapeutics to Present at the Jefferies Virtual Healthcare Conference

DUBLIN, Ireland, May 27, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
May 18, 2020 08:00 ET | Source: Nabriva Therapeutics US, Inc

National Burden of Macrolide-Resistant Streptococcus Pneumoniae in the United States From Blood and Respiratory Tract Cultures Approaches 40 Percent

DUBLIN, Ireland, May 18, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
May 11, 2020 16:01 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Updates

-Cash runway extended into the fourth quarter of 2020 through judicious resource management- -XENLETA managed care coverage and patient reimbursement continues to strengthen- -Potential...
May 11, 2020 07:00 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Therapeutics to Present at the BofA Securities 2020 Virtual Health Care Conference

DUBLIN, Ireland, May 11, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
May 08, 2020 07:00 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Therapeutics to Report First Quarter 2020 Financial Results on May 11, 2020

DUBLIN, Ireland, May 08, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
May 05, 2020 07:00 ET | Source: Nabriva Therapeutics US, Inc

XENLETA® (Lefamulin) Treatment Results in a Rapid Time-to-Clinical Response in Hospitalized Patients with Community-Acquired Bacterial Pneumonia (CABP)

DUBLIN, Ireland, May 05, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
April 09, 2020 07:00 ET | Source: Nabriva Therapeutics US, Inc

Centers for Medicare & Medicaid Services Issues Product-Specific J-Code for XENLETA

DUBLIN, Ireland, April 09, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
April 08, 2020 07:00 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference

DUBLIN, Ireland, April 08, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
March 12, 2020 16:01 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Therapeutics Reports Fourth Quarter and Year End 2019 Financial Results and Recent Corporate Highlights

-Prioritizing community opportunity for oral XENLETA given broad reimbursement coverage- -Reducing balance sheet risk through early paydown of a substantial portion of Hercules loan- -Pursuing...